Revenue
2018
2019
2020
2021
2022
2023
2024
2025
CRISPR Therapeutics AG (CRSP)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M | $719,000 | $289.6M | $3.1M | $41.0M | $5.2M | $247,000 | — |
| Research & development | $284.8M | $310.2M | $387.3M | $461.6M | $340.6M | $221.4M | $179.4M | $113.8M | $69.8M | $42.2M | $12.6M | $1.5M |
| Operating expenses | $668.1M | $503.9M | $593.7M | $674.4M | $541.4M | $355.2M | $242.8M | $162.1M | $105.6M | $73.3M | $26.0M | $6.6M |
| Operating income | −$664.6M | −$466.6M | −$222.5M | −$673.2M | $373.5M | −$354.4M | $46.7M | −$158.9M | −$64.6M | −$68.1M | −$25.7M | −$6.6M |
| EBITDAderived | −$645.1M | −$447.3M | −$202.7M | −$649.0M | $391.5M | −$345.3M | $51.5M | −$155.4M | −$61.6M | −$67.2M | −$25.6M | −$6.6M |
| Net income | −$581.6M | −$366.3M | −$153.6M | −$650.2M | $377.7M | −$348.9M | $66.9M | −$165.0M | −$68.4M | −$23.2M | −$25.5M | −$7.0M |
| Basic EPSper diluted share | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.97 | -$5.29 | $1.23 | -$3.44 | -$1.71 | -$1.89 | -$5.06 | $1.97 |
| Diluted EPSper diluted share | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.70 | -$5.29 | $1.17 | -$3.44 | -$1.71 | -$1.89 | -$5.06 | $1.97 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 29, 2026Form 4 | Patel NaimishChief Medical Officer | SellCommon Shares | 3.8K | $55.62 | $210.6K | 19.4K |
| Mar 23, 2026Form 4 | KASINGER JAMES R.General Counsel and Secretary | SellCommon Shares | 3.2K | $46.78 | $148.9K | 94.3K |
| Mar 23, 2026Form 4 | Kulkarni SamarthChief Executive Officer | SellCommon Shares | 10.0K | $46.78 | $468.7K | 255.5K |
| Mar 23, 2026Form 4 | Prasad RajuChief Financial Officer | SellCommon Shares | 3.7K | $46.78 | $173.5K | 15.6K |
| Mar 16, 2026Form 4 | Patel NaimishChief Medical Officer | SellCommon Shares | 3.1K | $48.26 | $152.0K | 13.1K |